1. In Vivo

Deals Shaping the Medical Industry (10/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Challenging a bid from Ventana Medical Systems, Cytyc (diagnostics and devices for cancer and women's health) intends to offer $A497mm ($374mm) for Australian in vitro diagnostics maker Vision Systems. (Sep.)

Cytyc plans to bid $A2.35 in cash for each ordinary share, a 10% premium to both Vision System's market average and the $A2.13 per share offer from Ventana last month. Vision says its shareholders will be evaluating both takeover bids. The company, founded in 1984, sells histology instruments and immunochemistry and in situ hybridization reagents to anatomical pathology laboratories through its Vision BioSystems division. Its products include the Bond and Autostainer rst staining systems; Peloris tissue processor; SL50 slide loading machine; and Novocastra antibodies (acquired through Vision's 2002 takeover of Novocastra Laboratories) for detection of cancer and infectious diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.